Limitations of traditional anticoagulants

Pharmacotherapy

Volumn 24, Issue 7 II, 2004, Pages

  Hawkins, David ^a  

^a MERCER UNIVERSITY   (United States)

Author keywords

Advantages; Anticoagulants; Direct thrombin inhibitors; Factor Xa inhibitor; Fondaparinux; Heparin; Limitations; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBIN; ARGATROBAN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 12A; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; FONDAPARINUX; HEPARIN; HERBACEOUS AGENT; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PLASMA PROTEIN; PROTEIN C; PROTEIN S; PROTHROMBIN; THROMBIN; THROMBIN INHIBITOR; THROMBOCYTE FACTOR 4; VITAMIN K GROUP; WARFARIN; XIMELAGATRAN;

BLEEDING; BLOOD CLOTTING; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; EMBRYOPATHY; FETAL HEMORRHAGE; FETUS DEATH; GARLIC; GINKGO BILOBA; GINSENG; HUMAN; OSTEOPOROSIS; PARTIAL THROMBOPLASTIN TIME; REVIEW; TERATOGENICITY; THROMBOCYTOPENIA; THROMBOEMBOLISM;

ANTICOAGULANTS; FACTOR XA; HEPARIN; HUMANS; POLYSACCHARIDES; WARFARIN;

EID: 3042842126     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.10.62S.36120     Document Type: Review

References (17)

1. Majerus PW, Tollefsen DM. Anticoagulant, thrombolytics, and antiplatelet drugs. In: Hardman JG, Limbird LE, eds. Goodman and Gilman's the pharmacological basis of therapeutics, 10th ed. New York: McGraw-Hill, 2001:1519-38.
2. Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001;119(suppl 1):S8-21.
3. Palareti G, Manotti C, D'Angelo A, et al. Thrombotic events during oral anticoagulant treatment: results of the inception-cohort, prospective, collaborative ISCOAT study. (Italian study on complications of oral anticoagulant therapy). Thromb Haemost 1997;78:1438-43.
4. van der Meer FJM, Rosendaal FR, Vandenbroucke JP, Briet E. Bleeding complications in oral anticoagulant therapy: an analysis of risk factors. Arch Intern Med 1993;153:1557-62.
5. Dutch Bypass Oral Anticoagulants or Aspirin (BOA) Study Group. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (the Dutch bypass oral anticoagulants or aspirin study): a randomised trial. Lancet 2000;355:346-51. (Erratum in Lancet 2000;355:1104.)
6. Dutch Bypass Oral Anticoagulants or Aspirin (BOA) Study Group. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (the Dutch bypass oral anticoagulants or aspirin study): a randomised trial. Lancet 2000;355:346-51. (Erratum in Lancet 2000;355:1104.)
7. Heck AM, DeWitt BA, Lukes AL. Potential interactions between alternative therapies and warfarin. Am J Health-Syst Pharm 2000;57:1221-30.
8. Hulse ML. Warfarin resistance: diagnosis and therapeutic alternatives. Pharmacotherapy 1996;16:1009-17.
9. Redman AR. Implications of cytochrome P450 2C9 polymorphisms on warfarin metabolism and dosing. Pharmacotherapy 2001;21:235-42.
10. Hirsh J, Warkentin TE, Shaughnessy SG, et al, Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001;119(suppl 1):S64-94.
11. Ambrosioni E, Strocchi E. Pharmacokinetics of heparin and low molecular weight heparins. Hemostasis 1990;20(suppl 1):94-7.
12. Warkentin TE, Barkin RL. Newer strategies for the treatment of heparin-induced thrombocytopenia. Pharmacotherapy 1999;19:181-95.
13. Dager WE, White RH. Treatment of heparin-induced thrombocytopenia. Ann Pharmacother 2002;36:489-503.
14. Raschke RA, Reilly BM, Guidry JR, et al. The weight-based heparin dosing nomogram compared with a "standard care" nomogram: a randomized controlled trial. Ann Intern Med 1993;119:874-81.
15. Verstraete M. Pharmacotherapeutic aspects of unfractionated and low-molecular-weight heparins. Drugs 1990;40:498-530.
16. Dahlman TC. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol 1993;168:1265-70.
17. Bauer KA, Hawkins DW, Peters PC, et al. Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents-the selective factor Xa inhibitors. Cardiovasc Drug Rev 2002;20:37-52.